Sionna Therapeutics is trading 5.6% lower at $4.58 on October 6, 2026, with biotech-sector weakness potentially weighing on the shares.
- Biotech ETF XBI is down 2.50% during the session, while broader major indexes are up.
- No new company-specific announcement or same-day catalyst surfaced in the available news search; the recent Phase 2a failure and pipeline reset are earlier context, not an established cause of the decline.
- No volume figure is available in the supplied price context.